Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders

Abstract The therapeutic effects of mesenchymal stromal/stem cells (MSCs) are mainly based on three characteristics: immunomodulation, tissue regeneration, and hematopoietic support. Cell therapy using culture-expanded MSCs is effective in some intractable bone and hemato-immune disorders; however,...

Full description

Bibliographic Details
Main Authors: Noriko Sugino, Tatsuo Ichinohe, Akifumi Takaori-Kondo, Taira Maekawa, Yasuo Miura
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Inflammation and Regeneration
Subjects:
Online Access:http://link.springer.com/article/10.1186/s41232-017-0038-5
id doaj-fd7fe3adfd114dd5ae933a75787de19c
record_format Article
spelling doaj-fd7fe3adfd114dd5ae933a75787de19c2020-11-25T00:47:36ZengBMCInflammation and Regeneration1880-81902017-04-013711710.1186/s41232-017-0038-5Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disordersNoriko Sugino0Tatsuo Ichinohe1Akifumi Takaori-Kondo2Taira Maekawa3Yasuo Miura4Department of Transfusion Medicine and Cell Therapy, Kyoto University HospitalDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima UniversityDepartment of Hematology/Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Transfusion Medicine and Cell Therapy, Kyoto University HospitalDepartment of Transfusion Medicine and Cell Therapy, Kyoto University HospitalAbstract The therapeutic effects of mesenchymal stromal/stem cells (MSCs) are mainly based on three characteristics: immunomodulation, tissue regeneration, and hematopoietic support. Cell therapy using culture-expanded MSCs is effective in some intractable bone and hemato-immune disorders; however, its efficacy is limited. In this article, we review the previous efforts to improve the clinical outcomes of cell therapy using MSCs for such disorders. We describe pharmacological targeting of endogenous bone marrow-derived MSCs as a crucial quality-based intervention to establish more effective MSC-based therapies.http://link.springer.com/article/10.1186/s41232-017-0038-5Mesenchymal stromal/stem cellHematopoiesisRegenerationImmunomodulationPharmacological modificationCell therapy
collection DOAJ
language English
format Article
sources DOAJ
author Noriko Sugino
Tatsuo Ichinohe
Akifumi Takaori-Kondo
Taira Maekawa
Yasuo Miura
spellingShingle Noriko Sugino
Tatsuo Ichinohe
Akifumi Takaori-Kondo
Taira Maekawa
Yasuo Miura
Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
Inflammation and Regeneration
Mesenchymal stromal/stem cell
Hematopoiesis
Regeneration
Immunomodulation
Pharmacological modification
Cell therapy
author_facet Noriko Sugino
Tatsuo Ichinohe
Akifumi Takaori-Kondo
Taira Maekawa
Yasuo Miura
author_sort Noriko Sugino
title Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
title_short Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
title_full Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
title_fullStr Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
title_full_unstemmed Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
title_sort pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
publisher BMC
series Inflammation and Regeneration
issn 1880-8190
publishDate 2017-04-01
description Abstract The therapeutic effects of mesenchymal stromal/stem cells (MSCs) are mainly based on three characteristics: immunomodulation, tissue regeneration, and hematopoietic support. Cell therapy using culture-expanded MSCs is effective in some intractable bone and hemato-immune disorders; however, its efficacy is limited. In this article, we review the previous efforts to improve the clinical outcomes of cell therapy using MSCs for such disorders. We describe pharmacological targeting of endogenous bone marrow-derived MSCs as a crucial quality-based intervention to establish more effective MSC-based therapies.
topic Mesenchymal stromal/stem cell
Hematopoiesis
Regeneration
Immunomodulation
Pharmacological modification
Cell therapy
url http://link.springer.com/article/10.1186/s41232-017-0038-5
work_keys_str_mv AT norikosugino pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders
AT tatsuoichinohe pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders
AT akifumitakaorikondo pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders
AT tairamaekawa pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders
AT yasuomiura pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders
_version_ 1725259581675798528